2022 World Conference on Lung Cancer (ePosters)-EP04.01-020. Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center

EP04.01-020. Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center

Back to course

Pdf Summary

The impact of Next-Generation Sequencing (NGS) on treatment choice among patients with metastatic Non-Small Cell Lung Cancer (NSCLC) was analyzed in a retrospective study conducted at the CHUM University Center. The study found that 47% of patients had an actionable mutation identified through NGS that was not identified by reflex testing for EGFR and ALK. This led to a change in treatment for 53% of patients who benefited from tyrosine-kinase inhibitors (TKIs). However, the significant delay in identifying actionable mutations prevented many patients from receiving targeted therapy. The study emphasizes the importance of early molecular profiling with NGS at the time of diagnosis of metastatic NSCLC in order to personalize patient treatments.<br /><br />The study analyzed the characteristics and treatment outcomes of patients with metastatic NSCLC. It found various actionable mutations, including EGFR, ALK, ROS1, MET, BRAF, BRCA, HER2, and NUTM1. The median age at diagnosis varied among the different mutation types. The study also examined the treatment course of patients with actionable mutations, showing the duration of different lines of treatment.<br /><br />Overall survival rates were analyzed for patients with actionable mutations compared to those with non-actionable mutations or no mutation. The study found that the five-year overall survival rate for patients with actionable mutations was 41.4%, compared to 35.8% for those with non-actionable mutations. However, there was no significant difference in overall survival between patients who received TKIs and those who did not.<br /><br />The study also examined co-mutations, including KRAS status and TP53 status, and their distribution among the patient population.<br /><br />In conclusion, NGS has become an essential tool in identifying actionable mutations and personalizing treatment choices for patients with metastatic NSCLC. However, the delay in identifying these mutations poses a challenge in delivering targeted therapy to patients in a timely manner. Implementing routine NGS at the time of diagnosis could help overcome this challenge and improve patient outcomes.

Asset Subtitle

Myriam Nait Ajjou

Meta Tag

Speaker Myriam Nait Ajjou

Topic Global Health, Health Services Research, and Health Economics - Cost Issues

Keywords

Next-Generation Sequencing

metastatic Non-Small Cell Lung Cancer

retrospective study

actionable mutation

tyrosine-kinase inhibitors

molecular profiling

overall survival rates

co-mutations

personalize treatment choices

improve patient outcomes